Your SlideShare is downloading. ×
0
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Biomarkers for Disease Flare by Emily Baechler Gillespie
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Biomarkers for Disease Flare by Emily Baechler Gillespie

1,319

Published on

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,319
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Genetics and Flare:Biomarkers for Disease Activity in SLE
    Emily Baechler Gillespie, Ph.D.
    University of Minnesota Department of Medicine
    Division of Rheumatic and Autoimmune Diseases
  • 2. Why Biomarkers for Disease Activity in SLE?
    Patient monitoring and management: Improve on existing lab tests
    Predicting risk of future activity: Limit or prevent flares
    Evaluating response to therapy: Promote drug development, “tailored therapy”
  • 3. Serum Protein Biomarkers for Systemic Lupus
    Identify proteins in the blood that are markers for lupus disease activity
    Measure these proteins over time in a large group of lupus patients
    Assess the ability of the proteins to predict changes in disease activity
    Provide foundation for development of a new clinical test for SLE
  • 4. Interferon signature: What is it?
    Interferon (IFN): Part of normal immune response
    IFN signature: Some SLE patients have an over-active IFN pathway
    Identified by measuring IFN-inducible mRNA transcripts and proteins
    A fingerprint for severe SLE
  • 5. Is there a fingerprint for lupus flare?
    Disease activity
    6 mo.
    9 mo.
    3 mo.
    Enroll
    12 mo.
    Time
  • 6. 172 proteins measured in 30 SLE patients and 15 controls
  • 7. 7 proteins measured in 81 SLE patients (longitudinal visits)
  • 8. 4 proteins measured in 267 SLE patients (longitudinal visits)
  • 9. 4 proteins measured in 373 SLE patients (single visits)
    Same proteins, more focus on clinical utility
  • 10. Results of LRI-Funded Work
    IFN-regulated chemokines
    The ‘traffic cops’ of the immune system
    Chemokine levels in SLE:
    Higher in active vs. inactive SLE
    Correlate with SLE activity, rising at flare and falling with remission
    A better indicator of lupus activity than standard clinical lab tests
    Bauer et al., PLoS Med 2006
  • 11. Do elevated chemokine levels predict future flare?
    Identify patients with mild or inactive disease44 with high chemokine levels (CK-high) 108 CK-intermediate 72 CK-low
    Compare frequency of flares during one year of clinical follow-up
  • 12. CK-high patients are at increased risk for future flare
    Bauer et al., Arthritis Rheum 2009
  • 13. Ongoing Studies
    Could this be the basis for a new clinical test for lupus?
    Opportunity to try therapeutic intervention
    Could this test identify people who are at risk for future development of lupus?
    New funding to test ANA+ subjects
    Potential to identify patients who are most likely to benefit from new drugs
  • 14. Acknowledgments
    University of MN
    Jason Bauer, PhD
    Hatice Bilgic, PhD
    Mehrnaz Hojjati, MD
    Thearith Koeuth
    Joe Wilson
    Carolyn Meyer
    ABCoN Collaborators
    Tim Behrens, MD(Genentech)
    Peter Gregersen, MD (Feinstein Institute)
    Michelle Petri, MD (Johns Hopkins)

×